Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Docetaxel

Docetaxel ▴ Docetaxel, a potent taxoid analog that primarily exerts its antineoplastic activity via tubulin stabilization and cell cycle arrest, is well established as a chemotherapeutic agent in the treatment of breast cancer. Docetaxel-containing neoadjuvant regimens have been investigated in terms of pathologic complete response (pCR) in four fully published phase III trials in women with early-stage or locally advanced breast cancer, and in terms of disease-free and overall survival in the largest trial, the National Surgical Adjuvant Breast and Bowel Project Protocol (NSABP) B-27. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Loading next page...
 
/lp/springer-journals/docetaxel-uFEALxrbof
Publisher
Springer Journals
Copyright
Copyright © 2006 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200605030-00007
Publisher site
See Article on Publisher Site

Abstract

▴ Docetaxel, a potent taxoid analog that primarily exerts its antineoplastic activity via tubulin stabilization and cell cycle arrest, is well established as a chemotherapeutic agent in the treatment of breast cancer. Docetaxel-containing neoadjuvant regimens have been investigated in terms of pathologic complete response (pCR) in four fully published phase III trials in women with early-stage or locally advanced breast cancer, and in terms of disease-free and overall survival in the largest trial, the National Surgical Adjuvant Breast and Bowel Project Protocol (NSABP) B-27.

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References